
Symbiotec Pharmalab IPO Gets 80% Subscription On First Day
The story in brief
Symbiotec Pharmalab Ltd's IPO received 80% subscription on the first day of bidding, with retail investors subscribing 95% and QIBs 35%. The offering, valued at up to Rs 6,350 crore, includes a fresh issue of Rs 150 crore and an OFS of Rs 1,607 crore. Shares are set to list on BSE and NSE on September 1. The company, a global leader in corticosteroid APIs, plans to use proceeds for debt repayment and corporate purposes.